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locations and sprains represented 37%, 27% were mainly 
contusions/abrasions, 23% had open wounds, and <1% major
abdominal injury. The visit reason codes for the remaining cases
included pain, other symptoms and conditions. Mean duration
of ED visit was 2.3 hours (median: 1.8). Mean cost per ED visit
was $460 (median: $325) for those treated and released and
$560 for those admitted (median: $427). On average, those
admitted spent 3 days (median: 2) in the hospital at a cost of
$8375 (median: $6340). CONCLUSIONS: Most bicycle related
injuries occurred in children or young adults,in the early evening,
involved only the cyclist and could be managed in the ED.
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OBJECTIVES: Drug costs represent a considerable cost item 
in the overall hospital budget. Within drug costs, oral and
injectable antibiotics are indeed one of the most relevant sources
of expenditure. This analysis is focused on the comparison
between the actual per patient consumption of antibiotics and
the Deﬁned Daily Dose (DDD) which is frequently used as an
indicator for inclusion of a drug in the Hospital Formulary and
subsequent purchase. METHODS: This research was based on
the analysis of the Antibiotics Request Forms (ARF’s), which
were forwarded by the Hospital Wards to the Pharmacy in the
Geriatric Hospital “U. Sestilli”, Ancona. The analysis was
focused on the daily per patient consumption (Prescribed Daily
Doses, PDD) of antibiotic treatments as compared to the DDD,
and on its cost (considering ofﬁcially published prices and hos-
pital discounts). RESULTS: In the period February–May, 2003,
2350 ARF’s were ﬁled, referring to prescriptions of antibiotics.
Of these, 1942 were eligible for analysis and concerned 976
patients. Total expenditure for antibiotics in such period was
63,727€; 25% of this was due to the ﬂuorochinolones currently
included in the Hospital Formulary (ATC J01MA): ciproﬂoxacin
and levoﬂoxacin. By comparing PDD’s with DDD’s, and assum-
ing equal to one the exact correspondence between PDD and
DDD of each drug, in 75% of prescriptions PDD’s did not cor-
respond to DDD’s. In particular, the PDD/DDD rate resulted
0.68 for injectable ciproﬂoxacin, and 1.1 for injectable lev-
oﬂoxacin: similarly, considering oral formulations, the two rates
were respectively 0.79 and 1.28. CONCLUSIONS: According to
the prescription practice of this Hospital and to the type of
patients seen, the inclusion in Hospital Formulary and purchase
of antibiotics based on the DDD’s might be misleading and could
result into an incoherent management of Pharmacy stock and
ﬁnancial assets.
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OBJECTIVES: The new G-DRG hospital payment system came
into effect in 2003. For a fully functional DRG-payment system
it is important that DRG groups are cost homogenous.
METHODS: To show the impact of innovations on the cost
homogenity of a DRG group, a cost study has been performed
as a sub-study of a clinical safety and feasibility analysis.
RESULTS: We used the bone growth protein rhBMP-2 (not yet
approved for Spine indication in Europe) additional to standard
fusion for spine surgery in 18 cases. RhBMP-2 has the potential
to reduce complication rates, avoids iliac crest bone graft har-
vesting and associated morbidities and ensures earlier return to
work. The relevant DRG for fusion procedures in our patient
group—with or without the usage of rhBMP-2—is I09B, relative
weight 2.875 and average costs of 8313.94€. Average costs have
been assessed in 536 patients. In our study we have assessed the
cost for spine fusions with and without the usage of rhBMP-2.
All costs have been calculated according to IneK calculations
rules. Average cost were in the none rhBMP-2 group 8388.41€
with average implant costs of 2576.17€. The results reﬂect very
well cost homogenity in the DRG group. Usage of rhBMP-2 adds
signiﬁcant drug cost (3422€). No signiﬁcant other cost offsets
apply. A total cost increase of 40.79% leads to an unacceptable
high cost variance in the I09B. CONCLUSIONS: Based on this
data one could conclude that specialized hospital wards in spine
surgery who attract more difﬁcult cases will be discriminated in
the G-DRG system as they will more often have to use innova-
tive high price drugs or medical devices. An expanded list of sup-
plementary fees for high cost innovative technologies could help
to reduce the costvariance within one DRG without the need to
further differentiate DRG groups.
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OBJECTIVES: Critical leg ischemia affects between 1.5 and 5%
of the population over 50 years old. Before opting for limb
amputation, two alternative therapies can be carried out: drug
therapy with prostanoid or Spinal Cord Stimulation (SCS). This
project, developed in the department of vascular surgery of the
Ospedale Maggiore in Bologna, was aimed at evaluating the
annual impact of these two treatments on department budget.
The annual impact of a therapy on department budget is deﬁned
as the difference between the cost of production and the DRG.
METHODS: The therapies cost of production was assessed
through an Activity Based Management (ABM) and Activity
Based Costing (ABC) approach. Activities were identiﬁed by
informal interviews with all hospital staff involved in the treat-
ment process. Costs were assessed by analyzing accounting data
supplied by the hospital administrative services. RESULTS: The
SCS pathway consists of two 3-days hospitalizations. Total cost
of SCS treatment was 10,390€ for responder patients (RP) and
3181.11€ for non-responders (NRP). Reimbursement for RP
consists of 2 DRG 4 6.430€ and DRG 4 + DRG 461 (2797.13€)
for NRP. The prostanoid pathway consists of one hospitalization
lasting between 7 and 28 days. This hospitalization can be
repeated if the clinical condition of the patient does not improve
after the ﬁrst cycle of treatment. The cost of this treatment varies
from a minimum of 4445.73€ for a cycle of 7 days to a maximum
of 9118.73€ for a 28 days cycle. Hospitalization for prostanoid
therapy is reimbursed by DRG 130 (3524.82€) or by DRG 131
(2443.36€). CONCLUSIONS: SCS costs are fully covered by
DRG while drug therapy costs are only partially covered.
Besides, the treatments differ as regards to the ability to forecast
patient total costs before starting treatment, which is low for
prostanoid therapy and high for SCS therapy.
